$4.440
-0.098 (-2.20%)Zum Schluss
GTBP-News
GTBP-Events
Selling Stockholders Plan to Sell Up to 13.5M Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 13.5M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
GT Biopharma Trading Halted Due to Volatility
GT Biopharma trading halted, volatility trading pause
GT Biopharma Receives FDA IND Clearance for GTB-5550
GT Biopharma announced IND clearance from the FDA for GTB-5550 in multiple myeloma. "Today's IND to expand the potential indications for GTB-5550 highlights the diverse utility of our Trike(R) platform," said Michael Breen, executive chairman and CEO of GT Biopharma. "The company remains focused on its two ongoing Phase 1 trials with GTB-5550 and GTB-3650, both of which are actively enrolling, and we look forward to the potential initiation of a third Phase 1 trial, pending receipt of non-dilutive grant funding."
GT Biopharma Doses First Patient in GTB-5550 Trial
GT Biopharma announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550, its B7-H3-targeted natural killer (NK) cell engager for solid tumors expressing B7-H3.
GT Biopharma Files to Sell 9.72M Shares of Common Stock
GT Biopharma files to sell 9.72M shares of common stock for holders
Ähnliche Artikel
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.